Compare Lowe`s Companies Inc (LOW) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lowe`s Companies Inc vs GeneDx Holdings Corp — how do they compare? Lowe`s Companies Inc trades at $186.7 (market cap $105.96B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Lowe`s Companies Inc is far larger — about 52.5× GeneDx Holdings Corp's market cap, and Lowe`s Companies Inc pays a 2.65% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lowe`s Companies Inc for 98 Days and GeneDx Holdings Corp for 19 Days on average.
| LOW | WGS | |
|---|---|---|
Market Cap | $105.96B | $2.02B |
Volume | 4,039,547 | 734,640 |
Sector | Consumer Cyclical | Health |
52-Week High | $287.39 | $167.51 |
52-Week Low | $179.50 | $34.51 |
Typical Hold Time | 98 Days | 19 Days |
Enterprise Value | $144.81B | $2.05B |
Dividend Yield | 2.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lowe's (LOW) trades at $186.00, up 2.46% with recent earnings beats but faces bearish technical signals. The stock shows solid fundamentals with a P/E of 15.96 and net margin of 7.35%, though revenue has declined from $96.2B in 2022 to $83.7B in 2025. Recent news highlights drone delivery innovation with DoorDash and Alphabet, while the home improvement sector faces macroeconomic headwinds.
Wall Street maintains a bullish consensus with a $244.09 price target (31 Buy, 19 Hold, 1 Sell), representing 31% upside potential. Key risks include housing market stagnation and competitive pressure from Home Depot. The negative shareholder equity position requires monitoring, but consistent dividend payments and operational cash flow strength provide stability.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
